BRPI0810081A2 - Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial - Google Patents
Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrialInfo
- Publication number
- BRPI0810081A2 BRPI0810081A2 BRPI0810081-0A2A BRPI0810081A BRPI0810081A2 BR PI0810081 A2 BRPI0810081 A2 BR PI0810081A2 BR PI0810081 A BRPI0810081 A BR PI0810081A BR PI0810081 A2 BRPI0810081 A2 BR PI0810081A2
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- brain diseases
- therapeutic agent
- diagnostic
- diagnostic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007099508A JP5098051B2 (ja) | 2007-04-05 | 2007-04-05 | ミトコンドリア障害脳疾患治療剤及び診断剤 |
| PCT/JP2008/055959 WO2008126693A1 (ja) | 2007-04-05 | 2008-03-27 | ミトコンドリア障害脳疾患治療剤及び診断剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0810081A2 true BRPI0810081A2 (pt) | 2014-10-21 |
Family
ID=39863800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0810081-0A2A BRPI0810081A2 (pt) | 2007-04-05 | 2008-03-27 | Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100120916A1 (pt) |
| EP (2) | EP3281642B1 (pt) |
| JP (1) | JP5098051B2 (pt) |
| KR (2) | KR101250576B1 (pt) |
| CN (1) | CN101678047B (pt) |
| AU (1) | AU2008239234B2 (pt) |
| BR (1) | BRPI0810081A2 (pt) |
| CA (1) | CA2682855C (pt) |
| NZ (1) | NZ580138A (pt) |
| RU (1) | RU2435595C2 (pt) |
| WO (1) | WO2008126693A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9095165B2 (en) | 2008-10-27 | 2015-08-04 | Sbi Pharmaceuticals Co., Ltd. | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient |
| JP5574329B2 (ja) * | 2010-05-06 | 2014-08-20 | 国立大学法人 岡山大学 | ミトコンドリアの蛍光染色方法 |
| JPWO2012067152A1 (ja) * | 2010-11-16 | 2014-05-12 | 三菱化学株式会社 | ＥｎｄｏｔｈｅｌｉａｌＰｒｏｔｅｉｎＣＲｅｃｅｐｔｏｒ蛋白質による脳梗塞の検査方法 |
| CN103717215B (zh) * | 2011-06-16 | 2016-08-17 | 思佰益药业股份有限公司 | 过敏性鼻炎的治疗剂 |
| US9351949B2 (en) | 2012-07-19 | 2016-05-31 | Sbi Pharmaceuticals Co., Ltd. | Prophylactic/therapeutic agent for influenza virus infection |
| US11633505B2 (en) | 2012-12-11 | 2023-04-25 | National University Corporation Kumamoto University | Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same |
| WO2015064447A1 (ja) * | 2013-10-29 | 2015-05-07 | 学校法人東京農業大学 | フラタキシン増強剤 |
| JP6602651B2 (ja) * | 2015-11-24 | 2019-11-06 | Ｓｂｉファーマ株式会社 | 神経発達障害改善剤 |
| CN109689038B (zh) * | 2016-09-02 | 2022-05-13 | 思佰益药业股份有限公司 | 含有5-氨基乙酰丙酸类的水性制剂 |
| US10590496B2 (en) * | 2016-11-29 | 2020-03-17 | Wedea Inc. | Composition for preventing and treating degenerative brain disease using novel lactic acid bacteria |
| KR102007980B1 (ko) * | 2016-11-29 | 2019-08-06 | (주) 위디어 | 신규 유산균을 이용한 퇴행성 뇌질환 예방 및 치료용 조성물 |
| WO2018221291A1 (ja) * | 2017-05-31 | 2018-12-06 | Ｓｂｉファーマ株式会社 | 過活動膀胱の予防剤または治療剤 |
| WO2018235728A1 (ja) * | 2017-06-23 | 2018-12-27 | Ｓｂｉファーマ株式会社 | 神経障害を改善するための医薬組成物 |
| RU2693627C2 (ru) * | 2017-11-03 | 2019-07-03 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
| AU2018371152B2 (en) | 2017-11-22 | 2024-02-08 | Khondrion Ip B.V. | Novel compounds for use in treating depression and migraine |
| TW202313061A (zh) | 2018-02-05 | 2023-04-01 | 日商泰拉強石股份有限公司 | 包含去氮黃素并睪固酮化合物或去氮黃素并膽固醇化合物的醫藥組成物 |
| JP6717989B2 (ja) | 2018-02-05 | 2020-07-08 | テラ・ストーン株式会社 | 細胞内でのａｔｐ産生を賦活するための補酵素因子の使用 |
| TWI717139B (zh) * | 2018-12-20 | 2021-01-21 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩自體免疫相關疾病的醫藥品的用途 |
| RU2744453C2 (ru) * | 2019-09-02 | 2021-03-09 | Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) | Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний |
| CN116829138A (zh) * | 2021-01-25 | 2023-09-29 | 学校法人顺天堂 | 肥厚型心肌病治疗剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0331665Y2 (pt) * | 1984-09-05 | 1991-07-04 | ||
| US5079262A (en) | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
| JP2767318B2 (ja) | 1990-04-11 | 1998-06-18 | 株式会社コスモ総合研究所 | ５―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤 |
| CA2158724A1 (en) * | 1994-09-20 | 1996-03-21 | Jue-Chen Liu | Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid |
| CZ291132B6 (cs) | 1995-03-10 | 2002-12-11 | Photocure Asa | Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem |
| GB9701675D0 (en) * | 1997-01-28 | 1997-03-19 | Bridgeman Keith | Composition for the treatment of parkinson's disease |
| JP3644809B2 (ja) * | 1997-10-15 | 2005-05-11 | コスモ石油株式会社 | 頭部用外用剤 |
| US20050065099A1 (en) * | 2003-09-19 | 2005-03-24 | Gail Walkinshaw | Treatment of mitochondrial diseases |
| JP4417865B2 (ja) | 2004-03-30 | 2010-02-17 | コスモ石油株式会社 | ５−アミノレブリン酸リン酸塩、その製造方法及びその用途 |
| JP4630087B2 (ja) | 2004-03-30 | 2011-02-09 | コスモ石油株式会社 | ５−アミノレブリン酸硝酸塩及びその製造方法 |
| JP4719483B2 (ja) | 2004-03-30 | 2011-07-06 | コスモ石油株式会社 | ５−アミノレブリン酸スルホン酸塩の製造方法 |
| EP1743621B1 (en) * | 2004-04-28 | 2014-03-05 | Cosmo Oil Co., Ltd. | Hair restorer |
| JP5034032B2 (ja) | 2004-09-29 | 2012-09-26 | Ｓｂｉファーマ株式会社 | 腫瘍診断剤 |
| EP1878421B1 (en) * | 2005-04-28 | 2019-04-03 | SBI Pharmaceuticals Co., Ltd. | External preparation for skin |
| EP1742038A1 (en) * | 2005-07-06 | 2007-01-10 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Device and method for determining the concentration of a substance |
| ITBO20050596A1 (it) | 2005-10-06 | 2006-01-05 | Gd Spa | Metodo ed unita' per il trasferimento di un prodotto in una macchina impacchettatrice intermittente |
-
2007
- 2007-04-05 JP JP2007099508A patent/JP5098051B2/ja active Active
-
2008
- 2008-03-27 NZ NZ580138A patent/NZ580138A/en unknown
- 2008-03-27 WO PCT/JP2008/055959 patent/WO2008126693A1/ja active Application Filing
- 2008-03-27 US US12/594,672 patent/US20100120916A1/en not_active Abandoned
- 2008-03-27 KR KR1020097020513A patent/KR101250576B1/ko active IP Right Grant
- 2008-03-27 BR BRPI0810081-0A2A patent/BRPI0810081A2/pt not_active Application Discontinuation
- 2008-03-27 EP EP17193845.9A patent/EP3281642B1/en active Active
- 2008-03-27 CA CA2682855A patent/CA2682855C/en active Active
- 2008-03-27 AU AU2008239234A patent/AU2008239234B2/en active Active
- 2008-03-27 EP EP08739088.6A patent/EP2135613B1/en active Active
- 2008-03-27 KR KR1020127034024A patent/KR101383418B1/ko active IP Right Grant
- 2008-03-27 RU RU2009136582/15A patent/RU2435595C2/ru active
- 2008-03-27 CN CN2008800108818A patent/CN101678047B/zh active Active
-
2012
- 2012-09-13 US US13/613,565 patent/US8927532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3281642B1 (en) | 2019-05-01 |
| CA2682855C (en) | 2015-06-23 |
| EP2135613B1 (en) | 2017-11-22 |
| NZ580138A (en) | 2011-04-29 |
| EP3281642A1 (en) | 2018-02-14 |
| CA2682855A1 (en) | 2008-10-23 |
| US8927532B2 (en) | 2015-01-06 |
| EP2135613A4 (en) | 2010-07-21 |
| WO2008126693A1 (ja) | 2008-10-23 |
| AU2008239234B2 (en) | 2012-11-08 |
| CN101678047B (zh) | 2013-05-22 |
| JP5098051B2 (ja) | 2012-12-12 |
| EP2135613A1 (en) | 2009-12-23 |
| JP2008255059A (ja) | 2008-10-23 |
| KR101383418B1 (ko) | 2014-04-08 |
| RU2435595C2 (ru) | 2011-12-10 |
| KR101250576B1 (ko) | 2013-04-03 |
| KR20130004943A (ko) | 2013-01-14 |
| AU2008239234A1 (en) | 2008-10-23 |
| CN101678047A (zh) | 2010-03-24 |
| US20100120916A1 (en) | 2010-05-13 |
| US20130011337A1 (en) | 2013-01-10 |
| RU2009136582A (ru) | 2011-04-10 |
| KR20100014718A (ko) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0810081A2 (pt) | Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial | |
| EP2119444A4 (en) | THERAPEUTIC AGENT FOR PAIN | |
| BRPI0819630A2 (pt) | Montagem de interface de paciente para terapia respiratória | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
| EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| BR112012004166A2 (pt) | colocação otimizada de cândula para aplicação de agentes terapêuticos ao cérebro | |
| BRPI0920030A2 (pt) | agente de oclusão do tecido | |
| BRPI0821145A2 (pt) | Agente terapêutico para prurido | |
| SI2056842T1 (sl) | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj | |
| BRPI1006733A2 (pt) | kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método | |
| BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
| BRPI0815551A2 (pt) | Tratamento através de hucbc de doença beta-amiloide | |
| EP2133083A4 (en) | THERAPEUTIC FOR SKIN OR MOLECULE INFECTIONS | |
| ATE530175T1 (de) | Therapeutische kombination für schmerzhafte medizinische zustände | |
| BRPI0810816A2 (pt) | Medicamento e métodos para tratar doenças auto-imune e câncer | |
| PL1981515T3 (pl) | Leczenie urazów i chorób mózgu za pomocą MAPC | |
| IL213703A (en) | Compounds for the treatment of pain and other diseases | |
| BRPI0811222A2 (pt) | Agente terapêutico para infarto cerebral. | |
| IL213606A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases | |
| BRPI0908300A2 (pt) | "dispositivo para estímulo de áreas do cérebro humano" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SBI PHARMACEUTICALS CO., LTD. (JP) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 33/26 , A61K 31/197 , A61K 49/00 , A61P 9/00 , A61P 9/10 , A61P 21/00 , A61P 25/00 , A61P 25/06 , A61P 25/16 , A61P 25/24 , A61P 25/28 , A61P 43/00 Ipc: A61K 49/00 (1980.01), A61P 21/00 (2000.01), A61P 2 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |